ArticleDigestive diseases (Basel, Switzerland)2025
Delayed Diagnosis of Hepatitis C Infection: Results of a Nationwide US Study.
Article in Digestive diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Factors associated with HCV coinfection and preferences for HCV screening services among people living with HIV/AIDS.BMC infectious diseases · 2026Article
- T cell dysfunction and metabolic disruption in chronic hepatitis C virus infection.Frontiers in immunology · 2026Review
- Mechanisms and Therapeutic Strategies for HCV/HBV-Associated B-Cell Non-Hodgkin's Lymphomas: A Viewpoint.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionUniversal screening of hepatitis C virus (HCV) was encouraged for individuals born 1945-65 in the USA in 2012. In 2014, efficacious treatments, namely, direct-acting antivirals (DAAs), were introduced. To examine their impact on the HCV care cascade, the proportion of and factors associated with delayed HCV diagnosis in the USA were examined in a national real-world cohort.
methodsWe retrospectively analyzed 69,989 adults with an HCV-related liver complication using the Merative™ Marketscan® Medicare Database (1/2007-12/2021). We defined delayed HCV diagnosis as a HCV diagnosis 2 years prior to or any time after the development of a liver complication, including cirrhosis, liver transplant, or hepatocellular carcinoma.
resultsThe cohort mean age was 55.8 years, 65.9% were male, and the vast majority (60,628 or 86.6%) had delayed HCV diagnosis with 47.7% occurring within 6 months of the complication. The proportion of delayed HCV diagnosis decreased from 89.1% before 2015 to 75.1% from 2015 to 2021. On multivariable analysis, complication diagnosis dates after 2015 and higher Charlson Comorbidity Index were associated with decreased odds of delayed HCV diagnosis, while male sex, mental health, and alcohol use were linked with increased odds of delayed HCV diagnosis.
conclusionDelayed HCV diagnosis occurred in almost 9 in 10 patients with chronic hepatitis C and liver complications overall and in 3 out of 4 even after DAA availability during the 2015-2021 time period. Further efforts are needed to improve HCV screening and linkage to care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.